ValuEngine downgraded shares of Quotient (NASDAQ:QTNT) from a buy rating to a hold rating in a research note issued to investors on Wednesday.
Other analysts have also issued reports about the company. Zacks Investment Research raised Quotient from a sell rating to a hold rating in a research report on Wednesday, October 10th. BidaskClub raised Quotient from a sell rating to a hold rating in a research report on Tuesday, November 20th.
Shares of Quotient stock opened at $6.64 on Wednesday. Quotient has a one year low of $2.78 and a one year high of $9.02.
Quotient (NASDAQ:QTNT) last issued its earnings results on Monday, November 5th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17). The company had revenue of $6.25 million during the quarter, compared to analyst estimates of $5.80 million. As a group, analysts anticipate that Quotient will post -1.92 EPS for the current fiscal year.
A number of institutional investors have recently modified their holdings of the stock. Clearbridge Investments LLC increased its position in Quotient by 934,831.7% in the 3rd quarter. Clearbridge Investments LLC now owns 2,477,569 shares of the company’s stock valued at $18,706,000 after buying an additional 2,477,304 shares in the last quarter. Lombard Odier Asset Management USA Corp increased its holdings in Quotient by 75.5% during the 3rd quarter. Lombard Odier Asset Management USA Corp now owns 351,000 shares of the company’s stock worth $2,650,000 after purchasing an additional 151,000 shares in the last quarter. Perceptive Advisors LLC increased its holdings in Quotient by 35.6% during the 3rd quarter. Perceptive Advisors LLC now owns 8,789,054 shares of the company’s stock worth $66,357,000 after purchasing an additional 2,306,034 shares in the last quarter. Highbridge Capital Management LLC increased its holdings in Quotient by 2,558.7% during the 3rd quarter. Highbridge Capital Management LLC now owns 2,036,337 shares of the company’s stock worth $15,375,000 after purchasing an additional 1,959,746 shares in the last quarter. Finally, Cpwm LLC bought a new stake in Quotient during the 3rd quarter worth approximately $634,000. 60.78% of the stock is owned by institutional investors and hedge funds.
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening.
See Also: What is the balance sheet?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.